România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharmadox healthcare ltd. - malta - fingolimodum - caps. - 0,5mg - imunosupresoare imunosupresoare selective

Uniunea Europeană - română - EMA (European Medicines Agency)

mylan ireland limited - fumarat de dimetil - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Uniunea Europeană - română - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - fumarat de dimetil - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lek pharmaceuticals d.d. - slovenia - dimetil fumarat - caps. gastrorez. - 120mg - imunosupresoare alte imunosupresoare

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lek pharmaceuticals d.d. - slovenia - dimetil fumarat - caps. gastrorez. - 240mg - imunosupresoare alte imunosupresoare

Uniunea Europeană - română - EMA (European Medicines Agency)

teva gmbh - fumarat de dimetil - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - fumarat de dimetil - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Uniunea Europeană - română - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomidă - scleroză multiplă - imunosupresoare selective - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Uniunea Europeană - română - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - scleroză multiplă - alte medicamente pentru sistemul nervos - fampyra este indicat pentru ameliorarea mersului pe jos la pacienții adulți cu scleroză multiplă cu handicap de mers pe jos (starea de invaliditate la scară extinsă 4-7).

Uniunea Europeană - română - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.